• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Evolution of SARS-CoV-2 spike trimers towards optimized heparan sulfate cross-linking and inter-chain mobility

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Dec 31;14(1):32174.
doi: 10.1038/s41598-024-84276-5. Evolution of SARS-CoV-2 spike trimers towards optimized heparan sulfate cross-linking and inter-chain mobility

Jurij Froese[SUP] 1 [/SUP], Marco Mandalari[SUP] 2 3 [/SUP], Monica Civera[SUP] 3 [/SUP], Stefano Elli[SUP] 2 [/SUP], Isabel Pagani[SUP] 4 [/SUP], Elisa Vicenzi[SUP] 4 [/SUP], Itzel Garcia-Monge[SUP] 5 [/SUP], Daniele Di Iorio[SUP] 1 [/SUP], Saskia Frank[SUP] 1 [/SUP], Antonella Bisio[SUP] 2 [/SUP], Dominik Lenhart[SUP] 6 [/SUP], Rudolf Gruber[SUP] 6 [/SUP], Edwin A Yates[SUP] 7 [/SUP], Ralf P Richter[SUP] 5 [/SUP], Marco Guerrini[SUP] 2 [/SUP], Seraphine V Wegner[SUP] 1 [/SUP], Kay Grobe[SUP] 8 [/SUP]



Affiliations
Abstract

The heparan sulfate (HS)-rich extracellular matrix (ECM) serves as an initial interaction site for the homotrimeric spike (S) protein of SARS-CoV-2 to facilitate subsequent docking to angiotensin-converting enzyme 2 (ACE2) receptors and cellular infection. More recent variants, notably Omicron, have evolved by swapping several amino acids to positively charged residues to enhance the interaction of the S-protein trimer with the negatively charged HS. However, these enhanced interactions may reduce Omicron's ability to move through the HS-rich ECM to effectively find ACE2 receptors and infect cells, raising the question of how to mechanistically explain HS-associated viral movement. In this work, we show that Omicron S proteins have evolved to balance HS interaction stability and dynamics, resulting in enhanced mobility on an HS-functionalized artificial matrix. This property is achieved by the ability of Omicron S-proteins to cross-link at least two HS chains, allowing direct S-protein switching between chains as a prerequisite for cell surface mobility. Optimized HS interactions can be targeted pharmaceutically, as an HS mimetic significantly suppressed surface binding and cellular infection specifically of the Omicron variant. These findings suggest a robust way to interfere with SARS-CoV-2 Omicron infection and potentially future variants.

Keywords: COVID-19; Heparan sulfate; Heparin; Intersegmental transfer; S-protein; SARS-CoV-2.

 
Back
Top Bottom